semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Carcinoma Documentation of Disease: 1.1 Subjects must have histologically confirmed invasive breast cancer and registration must occur within 14 months after the first histologic diagnosis of invasive breast cancer A core biopsy interpreted as invasive cancer meets this criterion; if no core biopsy is performed, the date of first histologic diagnosis will be the date of first surgical procedure that identifies invasive cancer (biopsy, lumpectomy or mastectomy) Neoadjuvant subjects should have no evidence of clinical T4 disease prior to chemotherapy and surgery; for neoadjuvant patients can be defined by either clinical stage prior to therapy or pathologic stage at surgery; if patient is eligible based on either, they are eligible for the study Bilateral breast carcinoma is allowed provided diagnoses are synchronous that is, within 3 months of one another and at least one of the two breast carcinomas meet the and neither Her-2 positive or inflammatory No evidence of metastatic disease 1.2 Her-2 negative, defined as In-situ hybridization (ISH) ratio of < 2.0 (if performed) Immunohistochemistry (IHC) staining of 0-2+ (if performed) Deemed to not be a candidate for Her-2 directed therapy. 1.3 Eligible tumor-node-metastasis (TNM) Stages
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 55.0-70.0,  Obesity Post-menopausal women between the ages of 55 and 70 without untreated medical illness Fluency in the English language Body mass index (BMI) ≥30 kg/m2 Able to walk for at least 10 minutes without needing to stop or without symptom onset  Significant untreated medical illness as evidenced by abnormal electrolytes or liver function tests Systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than or equal to 95 mmHg with or without treatment Abnormal thyroid stimulating hormone Abnormal late night salivary cortisol Untreated diabetes mellitus Any severe psychiatric condition Loss or gain of greater than or equal to 4 pounds in the past 6 months Pharmacologic treatment for weight loss within three months before screening Treatment with a very low calorie diet within six months before screening Use of systemic corticosteroids within three months
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Invasive Breast Cancer • histologically confirmed primary invasive breast cancer by core needle biopsy  • pathological diagnosed ductal carcinoma in situ or microinvasive breast cancer by core needle biopsy patient plans to receive neo-adjuvant system therapy
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 5.0-67.0,  Brain Concussion Cerebral Concussion Concussion, Intermediate Concussion, Mild Concussion, Severe Trauma, Nervous System Craniocerebral Trauma Brain Injuries Provide written informed consent Be between the ages of 4 and 67 years old Have a diagnosis of traumatic brain injury with a potential for concussion Subjects must have baseline vision correctable to within 20/500 bilaterally Subjects must have intact ocular motility Subjects must have ability to provide a complete ophthalmologic, medical and neurologic history as well as medications/drugs/alcohol consumed within the 24 hours prior  ER visit has been more than 2 weeks since the injury which may have caused the concussion Have received penetrating trauma or have a head CT demonstrating evidence of acute brain injury (subdural, epidural or intraparenchymal hemorrhage, edema/mass effect per attending radiologist read) Suffering burns, anoxic injury or multiple/extensive injuries resulting in any medical, surgical or hemodynamic instability Blind (no light perception), are missing eyes, do not open eyes It is pertinent that subjects be able to detect light and have both eyes in order for the eye tracking data to be effective and significant Previous history of: ocular motility dysfunction or extensive prior eye surgery Any physical or mental injury or baseline disability rendering task completion difficult Obvious intoxication or blood alcohol level greater than 0.2
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 30.0-70.0,  Breast Cancer A. Subjects who are asymptomatic and scheduled to undergo routine screening mammography OR B. Subjects scheduled for image guided needle biopsy as a result of findings obtained during standard of care imaging modalities AND C. Subjects has a prior mammogram and have been diagnosed with extremely or heterogeneously dense breast tissue (Density C or D)  Male by birth. 2. Individual is less than 30 and greater than 70 years old. 3. Contraindication to bilateral mammography or MRI 4. Subjects who are unable to read, understand and execute the informed consent procedure. 5. Subjects who have had mammography ultrasound or MRI examination performed on the day of the study prior to MIRA scan. 6. Subjects who have significant existing breast trauma. 7. Subjects who have undergone lumpectomy/mastectomy. 8. Subjects who have undergone breast reduction or breast augmentation. 9. Subjects who have undergone any other type of breast surgery, excluding surgical biopsy. 10. Subjects who have large breast scar / Breast deformation 11. Subjects who have undergone a breast needle biopsy or a surgical biopsy within the 6 month period prior to their intended enrollment into the study. 12. Subjects who have a temperature > 100° F (37.8C) degrees on the day of the MIRA imaging 13. Subjects who are pregnant or lactating 14. Subjects with known Raynaud's Disease 15. Subjects that are claustrophobic or have physical limitations that do allow them to sit in the system chair for the required imaging session. 16. Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices 17. Subject with kidney failure 18. Subject with known allergy to gadolinium 19. Subject with a history of multiple contrast MRI scans (more than 4 MRI scans over the past two year) 20. Inmates (45 CFR 46.306) or mentally disabled individuals 21. Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the purpose of planning cancer therapy) 22. Subjects currently participating in another investigational clinical study 23. Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Mass Women aged 18 years and above presenting for a diagnostic ultrasound secondary to a palpable mass, abnormal mammogram, follow-up ultrasound abnormality, or discharge were asked to participate in the study  Unable to give informed consent breast abnormality greater than one quadrant
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Healthy Premenopausal Period menstruating, pre-menopausal -  pregnant, lactating, post-menopausal, smoking, on birth control pills -
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  HIV Neurocognitive Impairment Stable HIV participants (CD4+ lymphocyte count > 350 cells/mm3) for at least two years prescribed their current cART regimen for at least six months) with mild to moderate cognitive impairment  Drug/alcohol abuse History of Parkinsons Alzheimers, stroke or traumatic brain injury diabetes mellitus renal insufficiency
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Breast Neoplasms Patients aged 30 or over 2. A uni-focal invasive ductal breast carcinoma or discrete uni-focal site which is deemed suitable for PDT within a multifocal invasive ductal carcinoma in a single breast. 3. Patients who have opted for mastectomy or wide local excision as primary treatment. 4. Capable of giving written informed consent  Patients who are not undergoing surgery as their primary treatment. 2. Patients undergoing surgery for DCIS without invasive breast cancer. 3. Patients with Lobular cancer 4. Patients with Necrotic tumours 5. Distant metastatic disease. 6. Patients will be excluded if they have porphyria or are sensitive to verteporfin (visudyne). 7. Patients who have severe cardiovascular disease. 8. Patients with severe or uncontrolled systemic disease e.g. hepatic impairment. 9. Patients with laboratory findings that make it undesirable for the patient to participate in the trial. 10. Male breast cancer patients 11. Pregnancy and lactation. 12. No patients with any psychiatric disorder making reliable informed consent impossible. 13. Patients will be excluded if taking part in any other trial of an experimental medicine 14. Patients will be excluded if taking endocrine therapy drugs that could confound the results
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female patient with breast cancer 2. Age > 18 years old 3. Available primary breast tumor sample with adjacent normal epithelial structures 4. Informed consent obtained and signed  Primary tumor size < 1cm 2. Surgical tumor sample without available adjacent normal epithelial structures
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 1.0-31.0,  B Acute Lymphoblastic Leukemia Central Nervous System Leukemia Ph-Like Acute Lymphoblastic Leukemia Testicular Leukemia Patients must be enrolled on APEC14B1 and consented to Screening on the Part A consent form prior to enrollment on AALL1131 White Blood Cell Count (WBC) Age 1-9.99 years: WBC >= 50 000/uL Age 10-30.99 years: Any WBC Age 1-30.99 years: Any WBC with Testicular leukemia CNS leukemia (CNS3) Steroid pretreatment Patients must have newly diagnosed B lymphoblastic leukemia (2008 World Health Organization [WHO] classification) (also termed B-precursor acute lymphoblastic leukemia); patients with Down syndrome are also eligible Organ function requirements for patients with Ph-like ALL and a predicted TKI-sensitive mutation: patients identified as Ph-like with a TKI-sensitive kinase mutation must have assessment of organ function performed within 3 days of study entry onto the dasatinib arm of AALL1131  With the exception of steroid pretreatment or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or any cancer diagnosed prior to the initiation of protocol therapy on AALL1131; patients cannot have secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy; patients receiving prior steroid therapy may be eligible for AALL1131 Patients with BCR-ABL1 fusion are not eligible for post-induction therapy on this study but may be eligible to enroll in a successor Children's Oncology Group (COG) Philadelphia positive (Ph+) ALL trial by day 15 Induction DS HR B-ALL patients with Induction failure or BCR-ABL1 Female patients who are pregnant are ineligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs Lactating females are not eligible unless they have agreed not to breastfeed their infant Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Patients ≥ 18 years of age with histologically proven infiltrating ductal carcinoma of breast no severe major organ dysfunction Patients must have adequate hematopoietic function as evidenced by: white blood cells (WBC) ≥ 3,000/μl absolute neutrophil count (ANC) ≥ 1,500/μl Platelet count ≥ 100,000/μl hemoglobin (HGB) ≥ 10 g/dl and not transfusion dependent Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 10% above upper limit of normal Individuals of child-bearing potential must have a negative serum or urine pregnancy test within 72 hours of Cycle 1 Day 1 World Health Organization (WHO) performance status of 0 or 1 No prior or concurrent cancer-associated chemotherapy, no initiation of new hormonal therapy Hormone receptor (estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor 2 (Her2)) status not specified Menopausal status not specified Patients or their legal representatives must be willing and able to provide written informed consent  Age < 18 Severe major organ dysfunction WHO performance status of >1 Prior cancer chemotherapy Stage IV Patients with symptomatic central nervous system (CNS) metastases from breast cancer Patients with a history of another invasive malignancy within the last 3 years History of loss of consciousness or transient ischemic attack within 12 months before study treatment initiation Patients who have known active HIV, Hepatitis B, or Hepatitis C infections Patients with any other condition which in the opinion of the investigator would preclude participation in the study